BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/28/2014 9:54:00 AM | Browse: 697 | Download: 765
Publication Name World Journal of Gastroenterology
Manuscript ID 6009
Country Türkiye
Received
2013-09-29 18:02
Peer-Review Started
2013-09-30 14:38
To Make the First Decision
2013-10-22 16:06
Return for Revision
2013-10-28 12:08
Revised
2013-11-15 03:38
Second Decision
2014-01-06 18:19
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2014-01-06 19:00
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
2014-03-12 13:37
Typeset the Manuscript
2014-04-17 09:19
Publish the Manuscript Online
2014-05-14 10:58
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Topic Highlights
Article Title Helicobacter pylori: Management in 2013
Manuscript Source Invited Manuscript
All Author List Yesim Ozen Alahdab and Cem Kalayci
Funding Agency and Grant Number
Corresponding Author Yesim Ozen Alahdab, MD, Department of Gastroenterology and Hepatology, Fatih Sultan Mehmet Education and Research Hospital, E5 Karayolu Uzeri Icerenkoy-Atasehir, 34752 Istanbul, Turkey. yesimalahdab@yahoo.com
Key Words Helicobacter pylori; First-line therapy; Second-line therapy; Rescue therapy
Core Tip Helicobacter pylori (H. pylori) is a prevalent, worldwide, chronic infection. The ideal therapy regimen for H. pylori infection should achieve an eradication rate ≥ 80%. Triple therapy remains an appropriate first-line therapy in areas of low clarithromycin resistance, and quadruple therapy should be the first-line therapy in areas of high clarithromycin resistance. Sequential therapy can be an alternative. Levofloxacin-containing regimens or concomitant therapies can be good choices for second-line therapy. Choice of treatment regimen for H. pylori infection should be done cautiously and antibiotic-resistance rates should be taken into consideration.
Publish Date 2014-05-14 10:58
Citation Alahdab YO, Kalayci C. Helicobacter pylori: Management in 2013. World J Gastroenterol 2014; 20(18): 5302-5307
URL http://www.wjgnet.com/1007-9327/full/v20/i18/5302.htm
DOI http://dx.doi.org/10.3748/wjg.v20.i18.5302
Full Article (PDF) WJG-20-5302.pdf
Full Article (Word) WJG-20-5302.doc
Manuscript File 6009-Review.doc
Answering Reviewers 6009-Answering reviewers.pdf
Copyright License Agreement 6009-Copyright assignment.pdf
Peer-review Report 6009-Peer reviewer(s).pdf
Scientific Editor Work List 6009-Scientific editor work list.doc